| General Information | |
|---|---|
| ZINC ID | ZINC000028128811 |
| Molecular Weight (Da) | 580 |
| SMILES | COc1ccc(S(=O)(=O)c2cc(OC)ccc2S(=O)(=O)c2ccc([C@H](C)NC(=O)c3ccc(C)cc3)cc2)cc1 |
| Molecular Formula | C30N1O7S2 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 153.598 |
| HBA | 7 |
| HBD | 1 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 40 |
| LogP | 5.658 |
| Activity (Ki) in nM | 891.251 |
| Polar Surface Area (PSA) | 132.6 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | + |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.92691886 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 24 |
| Fraction csp3 | 0.17 |
| Ilogp | 3.63 |
| Xlogp3 | 4.99 |
| Wlogp | 7.01 |
| Mlogp | 3.81 |
| Silicos-it log p | 4.75 |
| Consensus log p | 4.84 |
| Esol log s | -6.36 |
| Esol solubility (mg/ml) | 0.000252 |
| Esol solubility (mol/l) | 0.00000043 |
| Esol class | Poorly sol |
| Ali log s | -7.51 |
| Ali solubility (mg/ml) | 0.0000178 |
| Ali solubility (mol/l) | 3.06E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -10.6 |
| Silicos-it solubility (mg/ml) | 1.45E-08 |
| Silicos-it solubility (mol/l) | 2.50E-11 |
| Silicos-it class | Insoluble |
| Pgp substrate | |
| Log kp (cm/s) | -6.29 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 2 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 4.15 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.82 |
| Logd | 3.235 |
| Logp | 4.694 |
| F (20%) | 0.002 |
| F (30%) | 0.008 |
| Mdck | - |
| Ppb | 99.76% |
| Vdss | 0.211 |
| Fu | 0.92% |
| Cyp1a2-inh | 0.119 |
| Cyp1a2-sub | 0.926 |
| Cyp2c19-inh | 0.69 |
| Cyp2c19-sub | 0.938 |
| Cl | 1.253 |
| T12 | 0.02 |
| H-ht | 0.893 |
| Dili | 0.998 |
| Roa | 0.014 |
| Fdamdd | 0.97 |
| Skinsen | 0.016 |
| Ec | 0.003 |
| Ei | 0.007 |
| Respiratory | 0.001 |
| Bcf | 0.332 |
| Igc50 | 4.472 |
| Lc50 | 3.967 |
| Lc50dm | 4.952 |
| Nr-ar | 0.005 |
| Nr-ar-lbd | 0.096 |
| Nr-ahr | 0.08 |
| Nr-aromatase | 0.25 |
| Nr-er | 0.523 |
| Nr-er-lbd | 0.033 |
| Nr-ppar-gamma | 0.004 |
| Sr-are | 0.718 |
| Sr-atad5 | 0.007 |
| Sr-hse | 0.001 |
| Sr-mmp | 0.799 |
| Sr-p53 | 0.003 |
| Vol | 568.483 |
| Dense | 1.019 |
| Flex | 0.345 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.291 |
| Synth | 2.767 |
| Fsp3 | 0.167 |
| Mce-18 | 58 |
| Natural product-likeness | -0.984 |
| Alarm nmr | 2 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |